CX3CL1 and atherosclerosis: All of these molecules along with migration-driving CX3CL1 and CCR5 ligands are of particular interest, as they are currently being evaluated as putative therapeutic targets in atherosclerosis (the roles of the target cytokines, and the present therapeutic approaches and perspectives are reviewed in [31,39,44]).